Jun 15, 2026 08:02AM

Jun 15, 2026 08:00AM

Oct 29, 2024 08:02AM

Oct 29, 2024 08:00AM

Oct 22, 2024 08:11AM

Oct 22, 2024 08:00AM

Oct 3, 2024 08:00AM GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat

Jul 31, 2024 08:00AM

Jul 29, 2024 08:12AM

Jul 29, 2024 08:00AM

Jul 1, 2024 06:01AM

Jul 1, 2024 06:00AM

Jun 17, 2024 04:20AM

Dec 12, 2023 08:00AM GigaGen Receives FDA Clearance of IND to Begin Phase 1 Trial of Oncology Drug Candidate, GIGA-564, in Solid Tumors

Jul 20, 2023 08:16AM

Jul 20, 2023 08:15AM

May 11, 2023 08:30AM

Mar 6, 2023 07:05AM

Mar 6, 2023 07:00AM

Nov 3, 2022 09:00AM

Feb 24, 2022 06:12AM Grifols (GRFS) Collaborates with Endpoint Health to Develop and Commercialize Antithrombin III for Sepsis

Feb 24, 2022 06:00AM

Nov 4, 2021 09:00AM

Oct 19, 2021 11:18AM

Jun 1, 2021 10:30AM

Apr 15, 2021 11:59AM

Mar 9, 2021 03:15AM

Oct 9, 2020 06:27AM Grifols' (GRFS) anti-SARS-CoV-2 hyperimmune globulin begins clinical trial in patients with COVID-19

Oct 9, 2020 06:23AM

Aug 24, 2020 08:41AM

Jul 28, 2020 10:44AM

Jul 28, 2020 10:41AM

Jul 9, 2020 08:21AM

Jul 9, 2020 08:19AM

Jun 11, 2020 04:03AM Grifols starts production of its hyperimmune immunoglobulin as a potential passive immune therapy against COVID-19

May 7, 2020 09:00AM

Apr 28, 2020 09:00AM

Apr 20, 2020 09:00AM

Mar 25, 2020 05:25PM

Dec 12, 2019 09:24AM

Dec 6, 2019 03:43PM

Dec 6, 2019 03:42PM Grifols presents its latest Alzheimer's clinical trial data

Nov 7, 2019 10:00AM

Jul 4, 2019 11:51AM

Feb 7, 2019 12:33PM

Feb 7, 2019 12:31PM

Jan 23, 2019 07:36AM

Jan 23, 2019 07:30AM

Jan 8, 2019 07:39AM Grifols (GRFS) Reports FDA approval of Erytra Eflexis

Jan 8, 2019 07:37AM

323,570 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All